Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup

Health-care companies rose after a surprising new entrant in the obesity-drug bonanza from one biotech giant.

Amgen shares surged after the biotech giant said it saw encouraging signs from its injectable obesity drug MariTide. The biotech firm saw one of its largest gains since the aftermath of the financial crisis.

In another sign of the boundless appetite for weight-loss drugs, U.S. antitrust regulators said they would probe elements of a $16.5 billion deal with contract-drug maker Catalent aimed at boosting Novo Nordisk's production of the weight-loss drug Wegovy.

Write to Rob Curran at rob.curran@dowjones.com